Neurodegenerative diseases (ND) are characterized, especially, by the progressive loss of neurons, resulting in neuropsychomotor dysfunctions. Even with a high prevalence, NDs are treated with drugs that alleviate the symptoms of patients, but which develop adverse events and still do not inhibit the progression of the disease. Thus, within a new pharmacological perspective, this review aimed to verify the therapeutic potential of natural compounds of marine origin against ND. For this, an integrative review was carried out, according to the PRISMA methodology, which included steps such as: search, pre-selection and inclusion of articles. The results described revealed species such as Acaudina malpodioides, Holothuria scabra and Xylaria sp., which presented important evidence in relation to Alzheimer's, reducing the generation of ROS, presenting neuroprotective effects and reducing the concentration of Aβ peptide. Regarding Parkinson's disease (PD), another example of ND, the bioactive compounds from Holothuria scabra and Xylaria sp., showed to be able to reduce the degeneration of dopaminergic neurons, reduce the deposition of alpha synuclein and reduce the formation of Mutant Huntingtin protein (Mhtt). The other marine compounds and bioactive substances are also described in this review. In conclusion, the evaluated studies indicate that compounds of marine origin emerge as a promising source of bioactive compounds, revealing an important therapeutic potential for the treatment of ND.

Asthma is a prevalent chronic inflammatory disease that has gold standard treatment with corticosteroids, but these are associated with important long-term side effects. On this basis, Traditional Chinese Medicine contributes with therapeutic techniques such as the herbal Anti-Asthma Herbal Medicine Intervention (ASHMI). In this context, this study aims to evaluate the effectiveness of treatment with ASHMI compared to conventional therapy, considering the need for new therapeutic approaches. An integrative review was performed, according to the PRISMA methodology. Articles published between 2011 and 2021 that related Herbal Medicines of Traditional Chinese Medicine, asthma and corticosteroids were examined. The searches took place in October and November 2021 in the Scopus, PubMed, Web of Science, Google Scholar, and Scielo databases. The selection comprised steps such as: search, pre-selection and inclusion of articles. The results of the herbal medicine and its isolated components were demonstrated, with three studies being clinical trials with humans and four pre-clinical studies. From the results, the efficacy of the herbal medicine and its components compared to corticosteroids were evaluated. It was reported that ASHMI, unlike corticosteroids, does not suppress the hypothalamic-pituitary-adrenal axis and the immune system, having mild adverse effects